Company. 2800 Plymouth Road. Ann Arbor, Michigan 48105. PD 132301-2, an acyl-CoA: cholesterol acyltransferase (ACAT) inhibitor, was administered orally to cynomolgus monkeys for 2 wk at doses of 25, 50, 100, and 200 mg/kg to assess potential subacute toxicity. Sporadic episodes of soft feces and diarrhea increased in incidence from 100 to 200 mg/kg. Histopathologic alterations in adrenocortical cells of treated monkeys consisted of a dose-related decrease in cytoplasmic fine vacuolation and an increase in cytoplasmic eosinophilia most conspicuous in the zona fasciculata and reticularis. At 50, 100, and 200 mg/kg, a narrow discontinuous zone of cytotoxic cortical cell degeneration occurred in the outer zona fasciculata. Decreased fine vacuolation of cortical cells correlated ultrastructurally with reduced size and number of intracellular lipid vacuoles and biochemically with a dose-related decrease in adrenal total cholesterol (from 56 to 13% of control) and cholesteryl ester (from 51 to 3% of control) concentrations. Other ultrastructural changes noted in zona fasciculata cortical cells at all doses were an apparent increase in both smooth endoplasmic reticulum and variably sized autophagic vacuoles. Ovarian corpora lutea in some females at all doses had increased coarse vacuolation of luteal cells, foci of cellular degeneration, increased numbers of cholesterol clefts, and slight infiltrates of mononuclear cells. Sebaceous glands were atrophic in all treated monkeys due largely to a reduction in size and number of differentiated foam cells. Sebaceous gland reserve cells were hypertrophic and hyperplastic. Toxicity data from this study indicated that PD 132301-2 at 25-200 mg/kg targeted cholesterol-rich cells of the adrenals, ovaries, and skin adnexa.
INTRODUCTION
Acyl-CoA: cholesterol acyltransferase (ACAT; EC 2.3. 1.26) , an intracellular microsomal enzyme, catalyzes the esterification of long-chain fatty acyl-CoAs to free cholesterol (37) . Enzyme activity has been identified in a variety of tissues and cell types involved in cholesterol metabolism (39) . In small intestinal epithelial cells, ACAT regulates absorption of free cholesterol from the gut lumen (13, 14, 22, 23) . In liver, ACAT participates in generation of cholesteryl esters for lipoprotein synthesis and assists in regulating the intracellular storage pool of cholesterol for bile acid synthesis (1, 12) . In adrenal cortex and ovary, ACAT' and neutral cholesteryl ester hydrolase regulate the intracellular storage pool of cholesterol for synthesis of steroidogenic hormones (31, (38) (39) (40) (41) . ACAT activity has also been identified in placenta (33) , lactating mammary gland (32) , lung (19) , aorta (5) , macrophages (7, 27, 29, 30) , arterial smooth muscle cells (28, 36) , and fibroblasts of the lung (35) and skin (6, 36) . The physiologic role of ACAT in some of these tissues and cell types has not been clearly delineated. Cholesteryl esters can be a major form of tissue cholesterol in normal physiologic processes as well as pathologic conditions. Adrenal cortical and corpus luteal cells store large amounts of cholesteryl esters, which comprise the large cytoplasmic lipid vacuoles characteristic of these cells (4, 37, 41) . In skin, cholesteryl esters comprise nearly one-half of the total tissue cholesterol (18, 21) . In pathologic states such as atherosclerosis, cholesterol derived from serum lipoproteins accumulates as cholesteryl esters in foamy macrophages and smooth muscle cells that form the atherosclerotic plaques (5, 7) . Accumulation of cholesteryl esters in cells in the arterial intima is considered an important factor in development, progression, and persistence of these plaques (37) . ACAT inhibitors have the potential to limit both the intestinal absorption of cholesterol and the accumulation of cholesteryl esters in intimal plaques, thereby delaying or inhibiting the progression of atherosclerosis (3, 10, 34) . PD 132301-2 is a potent inhibitor of ACAT activity in vitro ( 16, 17) . Furthermore, this compound has hypolipidemic effects in a variety of animal models of dyslipidemia (16) . This report details the subacute toxicity profile of the ACAT inhibitor/hypolipidemic, PD 132301-2, when administered to cynomolgus monkeys at doses 25-200-fold greater than the lowest dose shown to be pharmacologically efficacious in animal models of dyslipidemia.
MATERIALS AND METHODS

Adult cynomolgus monkeys (Macaca fascicularis)
were obtained from Charles River Research Primates (Port Washington, NY). Animals were maintained in environmentally controlled rooms with a 12-hr light-dark cycle. Animals were housed individually in stainless-steel cages and had access to fresh water and dry Purina Certified Primate Chows . This study was conducted in accordance with current National Institutes of Health guidelines for animal welfare. PD Monkeys were observed daily for signs of toxicity. Physical and ophthalmic examinations were done pretest and at termination. Blood pressures were measured and electrocardiograms recorded pretest and during weeks 1 and 2. Recordings were taken prior to and 2 hr after dosing. Body weights were determined pretest, on day 7, and at study termination. Food consumption was assessed daily by visual inspection.
Hematology, clinical biochemistry, and urinalysis were performed by standard methods at pretest, during week 1, and at termination. Blood samples collected by venipuncture in EDTA anticoagulant were analyzed for red cell count, white cell count (total and differential), platelet count, hemoglobin, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin, and mean corpuscular he- moglobin concentration. Blood samples collected in sodium citrate anticoagulant were analyzed for prothrombin time and activated partial thromboplastin time. Serum was analyzed for high-density lipoproteins, low-density lipoproteins, very low density lipoproteins, triglycerides, cholesterol, glucose, bilirubin, calcium, phosphorus, sodium, chloride, potassium, urea nitrogen, creatinine, total protein, albumin, globulin, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, and total lactate dehydrogenase. Urine from high-dose and control monkeys was evaluated for specific gravity, pH, urobilinogen, ketones, protein, bilirubin, glucose, and occult blood. Urine sediment was examined microscopically.
At study termination, monkeys were euthanatized with an intravenous overdose of 4% Surital ~ sodium solution, exsanguinated, and necropsied. Samples of adrenal and liver were frozen for determination of tissue cholesteryl ester and total cholesterol concentrations. Brain, pituitary, thyroids, adrenals, liver, heart, spleen, kidneys, and gonads were weighed. Representative samples of brain, spinal cord, sciatic nerve, pituitary, thyroid, parathyroid, adrenal, pancreas, liver, gallbladder, tongue, parotid and mandibular salivary gland, esophagus, stomach, small and large intestine, trachea, lung, heart, aorta, thymus, spleen, tonsil, lymph nodes (mesenteric, tracheobronchial, and axillary), skin. mammary gland, skeletal muscle, stemebra, costochondral junction, kidney, urinary bladder, prostate, seminal vesicle, ovaries, uterus, cervix, and vagina were fixed in 10% buffered formalin. Eyes were fixed in 6% glutaraldehyde, and testes and epididymides were preserved in Bouin's fixative. Tissues were processed for paraffin embedding and tissue sections were stained with H&E.
These tissues from 200mg,'kg and control monkeys and potential target tissues. including adrenal, liver. ovary, skin. stomach, small intestine, and kidney, from monkeys given 25. 50 . and 100 mg kg were examined microscopically. Samples of adrenal cortex from each monkey were fixed in 2.5% glutaraldehyde. washed in cacodylate buffer. postfixed in 10o osmium tetroxide. dehy- Abbreviations: HDL = high-density lipoprotein; LDL = low-density lipoprotein; VLDL = very low density lipoprotein. a Values are mean ± SE: n = 4 (2 males. 2 females). b Significantly different from control (p = 0.05). drated in graded ethanol and propylene oxide, and embedded in Epon-Araldite resin. Three to 5 tissue sections from each monkey were sectioned at I Am, stained with Toluidine blue, and examined microscopically. Thin sections were cut from selected blocks containing representative zones of zona glomerulosa, fasciculata, and reticularis; stained with uranyl acetate and lead citrate; and examined ultrastructurally.
For biochemical determination of total and free cholesterol concentrations, samples of liver and adrenal were thawed, cleaned of extracapsular fat, weighed, and homogenized in 9.5 ml of isopropyl alcohol. Lipid was extracted from samples over 2- 3 days. Cholesterol content was measured using a modification of the enzymatic, colorimetric assay of Cooper (9) and coworkers, which has been previously described (2) . Cholesteryl ester mass concentrations were derived by multiplying the difference between free and total cholesterol concentration by the molar ratio of cholesteryl oleate/free cholesterol.
Statistical evaluation of tissue cholesterol and cholesteryl ester concentrations from 4 animals (2 male, 2 female) per treatment group was performed using a Student's t-test at p < 0.05. For serum lipoproteins, cholesterol, and triglycerides, statistical evaluation was performed for 4 animals (2 male, 2 female) per treatment group using the 1-factor analysis of variance at p < 0.05.
RESULTS
Clinical Findings
At 100 and 200 mg/kg, sporadic episodes of soft feces or diarrhea were observed at an incidence that was dose-related. No drug-related ophthalmologic, electrocardiographic, or blood pressure effects were identified. Intermittent occurrences of reduced food consumption were noted in 1 200-mg/kg male and female. Body weight loss of approximately 14% occurred in the other 200-mg/kg female during the course of the study. Other clinical observations noted in this animal were limited to minor episodes of soft feces and did not account for this loss in body weight. All monkeys survived to study termination.
Clinical Pathology
No clearly drug-related alterations were apparent in hematologic, clinical biochemical, or urinalysis parameters (data not shown). Serum cholesterol, triglyceride, and lipoprotein fraction data from monkeys at study termination are summarized in Table I .
Pathologic Findings
Small adrenals with or without thin adrenal cortexes were apparent macroscopically in 1 50-mg/kg male and female. Mean adrenal weights and adrenal-to-brain weight ratios (data not shown) for the ~m FIG. 3. -Zona fasciculata cortical cell from a control (A) and 200-mgkg (B) monkey, x 9.000. Notice that the adrenal cortical cell of PD 132301-2-treated monkey is depleted of lipid vacuoles and has increased cY10plasm ic lysosomes (residual bodies) and an increase in smooth endoplasmic reticulum. 200-mg/kg males were 84 and 70% of controls, respectively. Similar alterations in adrenal weights were not apparent in high-dose females.
PD 132301-2 induced histopathologic alterations in adrenal glands, ovaries, and skin. In adrenals, decreased cytoplasmic fine vacuolation, increased cytoplasmic eosinophilia, and relative nuclear enlargement were apparent in cortical cells of the zona fasciculata and zona reticularis in 2 males given 25 mg/kg and in all monkeys given higher doses. A dose-related increase in number and size of poorly defined areas of slight cortical cell hypertrophy were evident in zona fasciculata of nearly all treated animals. Cytotoxic degeneration of a thin discontinuous band of adrenal cortical cells in outer zona fasciculata subjacent to the zona glomerulosa was noted in I male and 1 female given 50 mg/kg, 2 males given 100 mg/ kg, and all monkeys given 200 mg/kg (Fig. 2 ). Minor infiltrates of small mononuclear cells into outer fasciculata were seen in 1 female given 50 mg/kg, I male and 1 female given 100 mg/kg, and both males and 1 female given 200 mg/kg.
Ultrastructurally, the adrenals of monkeys at all doses had a dose-related decrease in size and number of cytoplasmic lipid vacuoles in cortical cells of all zones (Fig. 3 ). In (Fig.  4) . Only minimal coarse vacuolation of luteal cells and few cholesterol clefts were noted in 1 control female; however, they were much less pronounced than in females receiving PD 132301-2. Foci of luteal cell degeneration and mineralization were also seen in several treated females. In 1 25-mg/kg female and in both 50-and 200-mg/kg females, foci of luteal degeneration were infiltrated by small numbers of mononuclear cells. In addition, decreased numbers of fine cytoplasmic vacuoles were apparent in luteal cells. Corpora lutea were not present in ovarian sections in 1 100-mg/kg female. Sebaceous gland atrophy evident in skin sections of all PD 132301-2-treated monkeys (Fig. 5 ) was due to decreased size and number of differentiated foam cells in central portions of glands. Reserve cells, which constituted the outer margins of these sebaceous glands, were both hypertrophic and hyperplastic.
Tissue Cholesterol Concentrations
Adrenals of PD 132301-2-treated monkeys had dose-related reductions in total cholesterol concentration, attributed largely to decreased cholesteryl ester content (Table II) . Mean cholesteryl ester concentrations in treated monkeys were reduced from 51 to 3% of control values over the dose range of 25-200 mg/kg. A trend toward reduced hepatic total cholesterol and cholesteryl ester concentrations was also noted, although differences did not achieve statistical significance.
DISCUSSION
Although considerable efforts have been made to develop drugs that inhibit ACAT activity, information pertaining to toxicologic or pathologic profiles of compounds in this drug class has not been forthcoming. Our findings indicate that the ACAT inhibitor, PD 132301-2, induced morphologic changes in lipid-rich cells of adrenal cortexes, ovarian corpora lutea, and skin sebaceous glands of chowfed, normolipidemic cynomolgus monkeys. Zonal cytotoxic degeneration in the zona fasciculata was considered the most significant, dose-limiting toxicologic effect.
Doses of PD 132301-2 employed in this study were 25-200-fold greater than doses that were minimally efficacious at reducing plasma lipids in hypercholesterolemic animals fed cholesterol-rich diets (16) . Plasma cholesterol and triglycerides were both reduced in eholesterol-fed, PD 13 2 301-2-treated guinea pigs and dogs at I mg/kg. In cholesterolfed rabbits, 5 mg/kg (lowest dose tested) reduced plasma cholesterol concentrations by 50%. In rats, the EDso for lowering an overnight rise in plasma cholesterol concentrations following a single feeding of a cholesterol-rich diet was 4-6 mg'kg when administered subcutaneously or orally. The reason that serum lipids were not altered in normolipidemic, chow-fed monkeys of the present study is uncertain. However, findings from Krause et al (16) suggest that efficacy for lowering plasma lipids is dependent in part on cholesterol intake or preexisting hypercholesterolemia. They found that 100 mg kg only lowered serum cholesterol and triglycerides slightly in normal chow-fed rats.
Depletion of fine vacuoles in adrenocortical and luteal cells and the reduction of differentiated sebaceous foam cells in skin adnexa were considered consequences of altered tissue cholesterol metabolism via ACAT inhibition rather than cytotoxicity. In adrenal glands and ovary, ACAT esterifies cholesterol for maintenance of an intracellular cholesterol storage pool used for steroidogenesis, and intracellular lipid vacuoles represent storage sites for excess cholesteryl esters (20, 24, 41) . In this study, depletion of fine vacuoles in adrenal cortical cells correlated with a dose-related decrease in adrenal concentration of total cholesterol due to depletion of cholesteryl esters. Reduced cholesterol and cholesteryl ester concentrations in the liver indicated that the reduction of cholesterol and cholesteryl ester mass was not adrenal-specific. Although total cholesterol and cholesteryl ester concentrations were not assessed in ovaries and skin, it was postulated that depletion of fine vacuoles in corpus luteal cells and the reduction of differentiated foam cells in sebaceous glands were a consequence of decreased synthesis or reduced storage of cholesteryl esters in these lipid-rich tissues.
Depletion of adrenal cortical cell lipid vacuoles and the corresponding reduction in tissue cholesteryl ester concentrations manifested at doses where concentrations of serum cholesterol or lipoprotein fractions were unchanged. This suggests that lipid depletion occurred as a direct effect of drug on cortical cells (e.g., ACAT inhibition) rather than from lowering of serum-derived substrate for synthesis of cholesteryl esters in tissues. Cortical cell lipid depletion has been observed with other lipid-regulating drugs such as the cholesterol synthesis inhibitors nafenopin and triparanol (20, 42) . However, lipid depletion with these compounds coincided with reductions of serum cholesterol concentrations, and cholesterol administration to nafenopin-treated rats completely reversed the adrenal lipid depletion. SER proliferation and increases in phagolysosomes in cortical cells ofPD 132301-2-treated monkeys have also been observed in rats treated with other hypolipidemic drugs including triparanol (42), mevinolin (25) , and nafenopin (20 The limited distribution of the cytotoxic adrenocortical lesion in monkeys administered PD 132301-2 is interesting, and such a distribution has not been reported by others who have studied adrenotoxicants in animals (8) . However, only few reports of chemical-induced adrenotoxin effects in monkeys are available for comparison (43, 44) . The discrete lesion pattern may represent a species-specific response due to regional differences in drug metabolism or accumulation.
Additional studies in our laboratory indicated that animal species differ in the sensitivity and zonal distribution of PD 132301-2-induced adrenotoxin effects. Dogs, guinea pigs, and rabbits given PD 132301-2 at doses far lower than the maximum employed in this study had more extensive cytotoxic injury in zona fasciculata and/or reticularis (11, 26) , attesting to the relative resistance of monkeys to adrenal toxicity of this hypolipidemic agent. Dogs were most sensitive to the adrenotoxin effects, in that a dose of 12 mg/kg induced near total ablation of the zona fasciculata and reticularis. Rats and hamsters are uniquely resistant to PD 132301-2induced adrenal toxicity in that doses as high as 1,000 mg/kg PD 132301-2 failed to induce significant adrenotoxicity. Variability in drug absorption, plasma drug levels, drug metabolism, or rates of excretion could all potentially account for differences in species sensitivity.
In summary, the ACAT inhibitor PD 132301-2 induced microscopic alterations in lipid-rich cells of the adrenal cortex, corpora lutea, and skin sebaceous glands. Depletion of tissue lipids in these tissues was an expected physiologic sequela to ACAT inhibition. Adrenotoxicity targeting the outer zona fasciculata was considered the most significant doselimiting effect in cynomolgus monkeys.
